Major players in the RNA analysis/ transcriptomics market are Affymetrix Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc, GE Healthcare, Illumina Inc, Qiagen N. V, F. Hoffmann-La Roche Ltd, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc, and Fluidigm Corporation.
New York, May 25, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RNA Analysis/ Transcriptomics Global Market Report 2022" - https://www.reportlinker.com/p06280880/?utm_source=GNW
The global rna analysis/ transcriptomics market is expected to grow from $5.27 billion in 2021 to $5.93 billion in 2022 at a compound annual growth rate (CAGR) of 12.6%. The market is expected to grow to $9.58 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%.
The RNA analysis/ transcriptomics market consists of sales of RNA analysis products and related services by entities (organizations, sole traders, and partnerships) that provide RNA analysis. Transcriptomics/RNA analysis is a study of the transcriptome under specific circumstances, environment, or in a specific cell using high-throughput methods.
The main types of products in the RNA analysis/ transcriptomics market are reagents/consumables, instruments, software.An instrument is a tool or device for doing a particular kind of work.
It is implemented in various areas including clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, RNA interference.Major technology involved in RNA analysis/ transcriptomics are microarrays, sequencing, polymerase chain reaction RNA interference.
RNA analysis is used in clinical diagnosis to detect different RNA species, pathogen RNA splice variants among others useful in the diagnosis of diseases.
The increasing demand for personalized medicine is expected to drive the growth of the RNA analysis/ transcriptomics market in the coming years.Personalized medicine refers to the customizing of medical treatment to each patient’s unique characteristics.
If scientists can implement the necessary practices and processes for personalized clinical care, RNA-Seq will be well-positioned to handle the massive clinical workload.According to a report on personalized medicines by US FDA, 11 drugs out of 44 new drugs approved in the year 2019 were personalized drugs.
Moreover, as per the Personalized Medicine Report 2020 published by the Personalized Medicine Coalition (PMC), the number of personalized medicines in the market more than doubled in 2020 in the USA. Therefore, the growing demand for personalized medicines propels the growth of the RNA analysis market.
Technological advancements and innovations in RNA analysis are emerging trends in the RNA analysis/ transcriptomics market.Technologies such as next-generation sequencing (NGS) and RNA interference (RNAi) improved precision and accuracy, which help researchers analyze the transcriptional activity.
For instance, Next-generation sequencing developed by Illumina is successfully used in fragmenting DNA/RNA into multiple pieces, adding adapters, sequencing the libraries, and reassembling them to form a genomic sequence.
In October 2020, 10x Genomics, a startup based in the USA acquired Cartana for an amount of $41.2 million. The acquisition of Cartana is expected to strengthen its approach to developing technologically advanced products. Cartana is a Sweden-based biotechnology player involved in developing in situ RNA analysis technology.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The countries covered in the RNA analysis/ transcriptomics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.
Read the full report: https://www.reportlinker.com/p06280880/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001